REG - Scancell Hlds - Agreement with major biotech

Scancell HoldingsAnnouncement

12/06/2024 07:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240612:nRSL1151Sa&default-theme=true

RNS Number : 1151S  Scancell Holdings Plc  12 June 2024

12 June 2024

 

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell Signs Agreement with Major International Biotechnology Company to
Evaluate an Antibody in the Glymab® Portfolio

 

Exclusivity has been granted to evaluate anti-glycan monoclonal antibody
generated via Scancell's proprietary GlyMab® platform.

 

Scancell Holdings plc (AIM: SCLP), the developer of novel oncology
immunotherapies today announces a major international biotechnology company,
will exclusively evaluate a Scancell investigational anti-glycan monoclonal
antibody for development of novel therapeutic products. Under the terms of the
agreement, Scancell has granted the company seven months exclusivity for
evaluation, which includes an $1M exclusivity payment payable within 30 days.

Professor Lindy Durrant, Chief Executive Officer of Scancell, said: "We are
very pleased to announce this agreement today with a leading international
biotechnology company. This is now the second anti-glycan monoclonal antibody
generated via our proprietary GlyMab® platform to be evaluated, the first now
being developed under a commercial licence agreement. This provides further
validation of the potential of our antibody platform to create novel,
differentiated antibody products.  Whilst the agreement is for an initial
exclusive evaluation period, there is an option to licence, and we look
forward to providing the market with any updates in due course."

The Scancell anti-glycan monoclonal antibody is a humanised antibody developed
by Scancell, using its novel anti-cancer GlyMab® platform. This is one of
five monoclonal antibodies currently in Scancell's antibody portfolio which
provides a rich reservoir of potential products for its in-house clinical
development and also for further deals.

 

About GlyMab®

Scancell is building a pipeline of differentiated anti-cancer monoclonal
antibodies ('mAbs') that target sugar motifs rather than proteins. The Company
currently has five novel mAbs in early-stage development and has the potential
to use its unique methodology to identify many more mAbs against glycan
targets in the future. All cells are covered by a dense layer of sugar
structures, called glycans, which change when a normal cell turns into a
cancer cell. These glycan motifs that are associated with tumour malignancies
can be targeted by antibodies such as the Company's GlyMab® portfolio. A
robust portfolio of patents and applications, as well as know-how, surround
the GlyMab® platform and generated drug candidates. The GlyMab® technology
is part of Scancell's antibody portfolio, joining AvidiMab®, a technology
that can be applied to all antibodies (regardless of the technology used to
generate them), enhancing their potency and ability to directly kill tumour
cells.

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014 (MAR).

 

 

-ENDS-

 

 For further information, please contact:
 Scancell Holdings plc                                                      +44 (0) 20 3709 5700

 Professor Lindy Durrant, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman
                                                                            +44 (0) 20 7710 7600

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker

 Nicholas Moore/Samira Essebiyea/Ben Good (Healthcare Investment Banking)

 Nick Harland (Corporate Broking))

 WG Partners LLP (Joint Broker)                                             +44 (0) 20 3705 9330

 David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

 Panmure Gordon (UK) Limited (Joint Broker)                                 +44 (0) 20 7886 2500

 Freddy Crossley/Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 ICR Consilium                                                              +44 (0) 20 3709 5700

 Mary-Jane Elliott/ Angela Gray/ Lindsey Neville                            scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRUUONRSAUNARR